Search - tctmd.com

Displaying 41 - 60 of 288

Sort: Relevancy | Date

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

News Daily News

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Yael L. Maxwell

July 01, 2021

Crushing Prasugrel Tabs Ups Platelet Inhibition Following Primary PCI

News Daily News

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Yael L. Maxwell

June 22, 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

May 18, 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

Ticagrelor’s Dominance Over Clopidogrel Again Questioned

News Daily News

Ticagrelor’s Dominance Over Clopidogrel Again Questioned

April 16, 2021

Platelet Tests Pre-CABG May Safely Shorten Washout Waits, Cut Costs

News Daily News

Platelet Tests Pre-CABG May Safely Shorten Washout Waits, Cut Costs

Yael L. Maxwell

March 09, 2021

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

TCTMD’s Top 10 Most Popular Stories for October 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

October 30, 2020

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

News Daily News

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

October 29, 2020

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in STEMI

Presentation TCT 2020

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in STEMI

Presenter: Byeong-Keuk Kim

October 14, 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

October 14, 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

News Daily News

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

October 09, 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

News Conference News ESC 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Yael L. Maxwell

September 08, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

August 10, 2020

Reduced-Dose Prasugrel Works Well in Older, Low-Weight ACS Patients

News Daily News

Reduced-Dose Prasugrel Works Well in Older, Low-Weight ACS Patients

July 21, 2020

TCTMD’s Top 10 Most Popular Stories for June 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2020

July 02, 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.